PFNX News
Archived Headlines
- July biotech blitz and the upcoming eye, ear and nose IPOs 07/22/14
- Eye disease biotech Avalanche Biotechnologies sets terms for $76 million IPO 07/21/14
- 14 US IPOs planned for the week of Jul 21 07/21/14
- Biotech Pfenex slashes proposed range to $8, adds shares 07/17/14
- 11 US IPOs planned for the week of Jul 14 07/14/14
See more
Year's fourth eye-focused biotech EyeGate Pharmaceuticals sets terms for $25 million IPO
EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $25 million by offering 2.0 million shares at a price range of $12 to $14. Insiders...read more
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat
This week's 10 IPOs largely disappointed as 70% were forced to price below the proposed range and 80% closed the week up 1% or less. Before this week, only 36% of IPOs this year had first-day pops of 1% or less. The enthusiasm for last week's ...read more
Thursday saw four IPOs raise under $100 million; two broke issue
Two of the four IPOs on Thursday broke issue after pricing below the range. Less than a quarter of IPOs in the past three months have traded down on the first day. The top performer, Intersect ENT (XENT), priced at the low end and gained 18%. The...read more
Biotech Pfenex prices IPO at $6, below downwardly revised $8 expectation
Pfenex, which is developing a biosimilar version of Roche’s Lucentis treatment for wet AMD, raised $50 million by offering 8.3 million shares at $6, below its downwardly revised $8 price expectation. The San Diego, CA-based company had initially planned to...read more